Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.

Fady Gh Haddad Koiji Sasaki Lewis Fady Nasr Nicholas James Short Tapan Mahendra KadiaSara DellasalaJorge CortesFranck Emmanuel NicoliniGhayas C IssaElias J Jabbour Hagop M Kantarjian

Published in: Cancer (2024)

Ponatinib yielded high cytogenetic and molecular responses in newly diagnosed chronic myeloid leukemia in chronic phase. Its use in the frontline setting is hindered by arterio-/vaso-occlusive and other severe toxicities.

Keyphrases

chronic myeloid leukemia
newly diagnosed
sickle cell disease
drug induced
early onset
single molecule